Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: J Clin Psychiatry. 2016 Feb;77(2):212–220. doi: 10.4088/JCP.14m09505

Table 4.

Hazard Analysis for 7-year Follow-up

Unadjusted Multivariable-adjusteda

Hazards Ratio 95% CI p-value Hazards Ratio 95% CI p-value
LDL Cholesterol

175+ mg/dL reference reference
153-174 mg/dL 1.11 0.91-1.31 0.25 1.19 0.99-1.43 0.06
134-152 mg/dL 1.08 0.91-1.27 0.43 1.17 0.97-1.40 0.09
114-133 mg/dL 1.07 0.91-1.27 0.42 1.10 0.91-1.32 0.32
<114 mg/dL 1.27 1.08-1.49 0.0039 1.26 1.05-1.50 0.012

HDL Cholesterol

66+ mg/dL reference reference
56 – 66 mg/dL 1.04 0.90-1.21 0.60 1.02 0.86-1.20 0.86
50 - 56 mg/dL 1.04 0.88-1.22 0.64 0.93 0.78-1.11 0.44
43 – 50 mg/dL 1.00 0.85-1.17 0.98 0.83 0.70-1.00 0.05
< 43 mg/dL 1.09 0.93-1.29 0.30 0.81 0.67-0.98 0.034

Total Cholesterol

260+ mg/dL reference reference
236 – 259 mg/dL 1.03 0.87-1.22 0.74 1.13 0.94-1.35 0.21
216 – 235 mg/dL 1.12 0.95-1.32 0.17 1.20 1.00-1.44 0.05
195 - 215 mg/dL 1.06 0.89-1.25 0.52 1.09 0.91-1.31 0.37
< 195 mg/dL 1.18 1.00-1.39 0.05 1.14 0.95-1.36 0.17

Triglycerides

185+ mg/dL reference reference
136 – 184 mg/dL 0.94 0.80-1.10 0.44 0.97 0.81-1.15 0.70
106 – 135 mg/dL 0.91 0.78-1.07 0.27 1.01 0.85-1.20 0.95
80 – 105 mg/dL 0.93 0.79-1.09 0.37 1.05 0.88-1.26 0.56
< 80 mg/dL 0.81 0.69-0.96 0.014 0.97 0.80-1.17 0.74
a

Adjusted for WHI trial arm, BMI, lipid-lowering medication, blood pressure, smoking status, coronary heart disease, stroke, peripheral artery disease, age, U.S. region, ethnicity, marital status, health insurance, alcohol consumption, leisure-time physical activity, cancer, income, education, diabetes, thyroid disease, and colitis